keyword
https://read.qxmd.com/read/38641335/pharmacokinetics-of-edoxaban-15%C3%A2-mg-in-very-elderly-patients-with-nonvalvular-atrial-fibrillation-a-subanalysis-of-the-eldercare-af-study
#1
JOURNAL ARTICLE
Takeshi Yamashita, Yoshiyuki Igawa, Masayuki Fukuzawa, Takuya Hayashi, Stefanie Hennig, Ken Okumura
BACKGROUND:  We evaluated the pharmacokinetics (PK) of low-dose (15 mg) edoxaban in very elderly patients (≥80 years) with nonvalvular atrial fibrillation (NVAF) and high bleeding risk. METHODS:  This subanalysis of the phase 3, randomized, double-blind, placebo-controlled, multicenter ELDERCARE-AF study evaluated edoxaban plasma concentrations and compared them with the Japanese population of the ENGAGE AF-TIMI 48 and Japanese severe renal impairment (SRI) studies...
April 19, 2024: Thrombosis and Haemostasis
https://read.qxmd.com/read/38607465/a-case-of-multidrug-resistant-intractable-pylephlebitis-and-intra-abdominal-abscess-due-to-perforated-appendicitis-successfully-treated-with-open-abdominal-management
#2
JOURNAL ARTICLE
Yu Norimatsu, Nobuyuki Takemura, Kaoru Yoshikawa, Kyoji Ito, Fuyuki Inagaki, Fuminori Mihara, Kazuhiko Yamada, Norihiro Kokudo
BACKGROUND: Pylephlebitis, a rare and lethal form of portal venous septic thrombophlebitis, often arises from infections in regions drained by the portal vein. Herein, we report a case of peritonitis with portal vein thrombosis due to acute severe appendicitis, managed with intensive intraperitoneal drainage via open abdominal management (OAM). CASE PRESENTATION: A 19-year-old male with severe appendicitis, liver abscesses, and portal vein thrombosis developed septic shock and multi-organ failure...
April 12, 2024: Surgical Case Reports
https://read.qxmd.com/read/38601172/adrenal-infarction-with-latent-myelodysplastic-myeloproliferative-neoplasm-unclassifiable-with-jak2-v617f-mutation
#3
Shunichiro Yasuda, Momoko Chiba, Rie Nishitani, Takako Watanabe
KEY CLINICAL MESSAGE: Hematopoietic neoplasms can cause adrenal infarction. In cases of thrombosis occurring at uncommon sites, it is necessary to consider evaluating for the JAK2 V617F mutation, even in the absence of notable abnormalities in blood counts. ABSTRACT: Adrenal infarction, a rare ailment, has been sporadically linked to hematopoietic neoplasms. A 46-year-old male encountered left adrenal infarction, which coincided with a progressive rise in platelet counts...
April 2024: Clinical Case Reports
https://read.qxmd.com/read/38592606/frailty-as-an-effect-modifier-in-randomized-controlled-trials-a-systematic-review
#4
Aaron Yao, Linhui Gao, Jiajun Zhang, Joyce M Cheng, Dae Hyun Kim
BACKGROUND: The effect of clinical interventions may vary by patients' frailty status. Understanding treatment effect heterogeneity by frailty could lead to frailty-guided treatment strategies and reduce overtreatment and undertreatment. This systematic review aimed to examine the effect modification by frailty in randomized controlled trials (RCTs) that evaluate pharmacological, non-pharmacological, and multicomponent interventions. METHODS: We searched PubMed, Web of Science, EMBASE, and ClinicalTrial...
April 9, 2024: Journal of General Internal Medicine
https://read.qxmd.com/read/38586812/may-thurner-syndrome-the-worst-case-scenario
#5
Marta Costa, Gonçalo Ferreira, Dora Gomes, Catarina Oliveira, Nelson Domingues
May-Thurner syndrome (MTS) is caused by compression of the left common iliac vein by the right common iliac artery against the spinal column. It can range from asymptomatic or present with subtle and unspecific signs and symptoms and rarely exhibit severe complications such as pulmonary embolism (PE). The diagnosis is confirmed by typical imaging findings. Treatment may include conservative measures, anticoagulation, endovascular or even surgical options. We report the case of a 20-year-old female who presented with cardiac arrest caused by an acute massive PE...
March 2024: Curēus
https://read.qxmd.com/read/38583107/trends-in-oral-anticoagulant-use-and-individual-expenditures-across-the-united-states-from-2014-to-2020
#6
JOURNAL ARTICLE
Omar S Alkhezi, Leo F Buckley, John Fanikos
BACKGROUND: Landmark clinical trials have expended the indications for the direct oral anticoagulants (DOACs), but contemporary data on usage and expenditure patterns are lacking. OBJECTIVE: This study aimed to assess annual trends in oral anticoagulant (OAC) utilization and expenditure across the United States (US) from 2014 to 2020. METHODS: We utilized the Medical Expenditure Panel Survey (MEPS) to study the trends of use and expenditures of warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban between 2014 and 2020 in the US...
April 7, 2024: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://read.qxmd.com/read/38577748/tolvaptan-therapy-for-edema-in-patients-with-chronic-kidney-disease
#7
JOURNAL ARTICLE
Li Zhou, Qianqian Xu, Xuehua Xi, Xueying Yu, Wenge Li
OBJECTIVE: Tolvaptan is a vasopressin V2 receptor antagonist that is commonly prescribed to alleviate edema associated with renal diseases. However, the clinical benefits of tolvaptan in chronic kidney disease (CKD) remain unclear. This study aimed to evaluate the effectiveness of tolvaptan in managing edema caused by CKD. MATERIALS AND METHODS: The efficacy and treatment regimen of tolvaptan were assessed in a cohort of 96 patients with renal edema and CKD. During the treatment, the patients' creatinine (CR), uric acid (UA), and estimated glomerular filtration rate (eGFR) were monitored as important indicators of kidney function...
April 5, 2024: Clinical Nephrology
https://read.qxmd.com/read/38567679/clinical-guideline-on-reversal-of-direct-oral-anticoagulants-in-patients-with-life-threatening-bleeding
#8
JOURNAL ARTICLE
Oliver Grottke, Arash Afshari, Aamer Ahmed, Eleni Arnaoutoglou, Daniel Bolliger, Christian Fenger-Eriksen, Christian von Heymann
BACKGROUND: Anticoagulation is essential for the treatment and prevention of thromboembolic events. Current guidelines recommend direct oral anticoagulants (DOACs) over vitamin K antagonists in DOAC-eligible patients. The major complication of anticoagulation is serious or life-threatening haemorrhage, which may necessitate prompt haemostatic intervention. Reversal of DOACs may also be required for patients in need of urgent invasive procedures. This guideline from the European Society of Anaesthesiology and Intensive Care (ESAIC) aims to provide evidence-based recommendations and suggestions on how to manage patients on DOACs undergoing urgent or emergency procedures including the treatment of DOAC-induced bleeding...
May 1, 2024: European Journal of Anaesthesiology
https://read.qxmd.com/read/38546285/management-of-isolated-distal-deep-vein-thrombosis
#9
REVIEW
Marc Righini, Helia Robert-Ebadi
<b/>Isolated distal deep vein thrombosis (DVT) represents up to 50% of all lower limb DVT in ultrasound series and is a frequent medical condition, which management is not well established. Data arising from registries and non-randomized studies suggest that most distal DVTs do not extend to the proximal veins and have an uneventful follow-up when left untreated. This data had some impact on international recommendations like the American College of Chest Physicians (ACCP), whose last version stated that ultrasound surveillance might be an option for selected low-risk patients...
March 28, 2024: VASA. Zeitschrift Für Gefässkrankheiten
https://read.qxmd.com/read/38541902/clinical-characteristics-and-incidence-of-hemorrhagic-complications-in-patients-taking-factor-xa-inhibitors-in-spain-a-long-term-observational-study
#10
JOURNAL ARTICLE
Carlos Escobar, Beatriz Palacios, Miriam Villarreal, Martín Gutiérrez, Margarita Capel, Ignacio Hernández, María García, Laura Lledó, Juan F Arenillas
Objective. To analyze the clinical characteristics of patients taking Factor Xa inhibitors (FXai), either direct FXai or enoxaparin (only in active cancer patients), and to estimate the incidence of and risk factors for major bleeding during FXai use. Methods. A retrospective cohort study, which included secondary data from computerized health records of primary care centers and hospitals in seven Spanish Autonomous Communities. Results. 9374 patients were analyzed, with 8972 taking direct FXai and 402 enoxaparin...
March 14, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38534886/drug-drug-interactions-of-fxi-inhibitors-clinical-relevance
#11
REVIEW
Nicola Ferri, Elisa Colombo, Alberto Corsini
Inhibitors of the factor FXI represent a new class of anticoagulant agents that are facing clinical approval for the treatment of acute coronary syndrome (ACS), venous thromboembolism (VTE), and stroke prevention of atrial fibrillation (AF). These new inhibitors include chemical small molecules (asundexian and milvexian), monoclonal antibodies (abelacimab, osocimab, and xisomab), and antisense oligonucleotides (IONIS-FXIRX and fesomersen), and thus, they have very peculiar and different pharmacokinetic and pharmacodynamic properties...
March 21, 2024: Hematology Reports
https://read.qxmd.com/read/38523519/effectiveness-and-safety-of-different-oral-anticoagulants-with-p-glycoprotein-cyp3a4-inhibitors-a-network-meta-analysis
#12
Siyu Yang, Ye Xu, Yang Zhang, Dandan Li, Xingang Li
BACKGROUND: Metabolism of oral anticoagulants (OAC) is affected by P-glycoprotein (P-gp)/ CYP3A4 enzyme. However, the P-gp/CYP3A4 inhibitors are unavoidably used with OACs. METHODS: Medline, Cochrane, and Embase were systematically searched for randomized controlled trials and cohort studies from inception till 23rd November, 2022 to assess the safety and effectiveness of OACs when concomitantly used with P-gp/CYP3A4 inhibitors. The primary outcomes were major bleeding and gastrointestinal (GI) bleeding...
March 22, 2024: Current Pharmaceutical Design
https://read.qxmd.com/read/38516287/mechanical-thrombectomy-using-double-stent-retriever-technique-for-acute-ischemic-stroke-following-embolism-from-the-pulmonary-vein-stump-after-left-upper-lobectomy-a-case-report
#13
Haruki Hirata, Yuta Kaneshiro, Yumiko Urano, Keiji Murata
Acute ischemic stroke (AIS) following pulmonary lobectomy, which is traditionally attributed to air embolism and atrial fibrillation (AF), may occur after thrombus formation in the pulmonary vein stump (PVS). Herein, we document the mechanical thrombectomy (MT) of a carotid bifurcation occlusion post-left upper lobectomy (LUL) to manage AIS. A 76-year-old male with a history of diabetes, dyslipidemia, and a treated dural arteriovenous fistula at the transverse sigmoid junction, with no history of AF, successfully underwent LUL for a pulmonary tumor...
March 2024: Curēus
https://read.qxmd.com/read/38511316/effectiveness-and-safety-of-edoxaban-compared-with-apixaban-in-elderly-patients-with-nonvalvular-atrial-fibrillation-a-real-world-population-based-cohort-study
#14
JOURNAL ARTICLE
Richard Chiv, Sarah Beradid, Samy Suissa, Christel Renoux
BACKGROUND: The very elderly (≥80 years) are at high risk of nonvalvular atrial fibrillation and thromboembolism. Given its recent approval, the comparative effectiveness and safety of edoxaban in this population, relative to the commonly used apixaban, remain unknown. METHODS: Using the United Kingdom Clinical Practice Research Datalink, we identified a cohort of patients aged ≥80 with incident nonvalvular atrial fibrillation and newly treated with edoxaban or apixaban between 2015 and 2021...
March 21, 2024: Stroke; a Journal of Cerebral Circulation
https://read.qxmd.com/read/38510285/comparing-anticoagulation-strategies-for-venous-thromboembolism-associated-with-active-cancer-a-systematic-review-and-meta-analysis
#15
JOURNAL ARTICLE
Tomohiro Fujisaki, Daisuke Sueta, Eiichiro Yamamoto, Conor Buckley, Guilherme Sacchi de Camargo Correia, Julia Aronson, Paulino Tallón de Lara, Koichiro Fujisue, Hiroki Usuku, Kenichi Matsushita, Roxana Mehran, George D Dangas, Kenichi Tsujita
BACKGROUND: Current guidelines recommend several direct oral anticoagulant agents (DOACs) equally for managing cancer-associated venous thromboembolism (VTE). OBJECTIVES: The aim of this study was to assess the efficacy and safety of DOACs in patients with active cancer. METHODS: Literature searches were conducted in PubMed, Embase, and Cochrane Central in November 2022. Randomized controlled trials investigating anticoagulation strategies (vitamin K antagonists, parenteral anticoagulation [eg, low-molecular weight heparin], and DOACs) for VTE in patients with active cancer were identified for network meta-analysis...
February 2024: JACC CardioOncology
https://read.qxmd.com/read/38464984/prescribing-patterns-and-outcomes-of-edoxaban-in-atrial-fibrillation-patients-from-asia%C3%A3-one-year-data-from-the-global-etna-af-program
#16
JOURNAL ARTICLE
Jong-Il Choi, Songsak Kiatchoosakun, Panyapat Jiampo, Hung Fat Tse, Yannie Oi Yan Soo, Chun-Chieh Wang, Chang Hoon Lee, Ladislav Pecen, Martin Unverdorben, Raffaele De Caterina, Paulus Kirchhof
Background: This study reports prescribing patterns and the 1-year effectiveness and safety of edoxaban in an Asian cohort of Edoxaban Treatment in routiNe clinical prActice (ETNA)-Atrial Fibrillation (AF) patients. Methods and Results: The Global ETNA-AF program integrates prospective, observational, noninterventional regional studies, collecting data on characteristics and clinical outcomes of patients with AF receiving edoxaban for stroke prevention. Baseline characteristics, medical history, and 1-year clinical event rates were assessed in patients from South Korea, Taiwan, Hong Kong, and Thailand...
March 8, 2024: Circulation reports
https://read.qxmd.com/read/38460663/air-pollution-and-serious-bleeding-events-in-high-risk-older-adults
#17
JOURNAL ARTICLE
Rindala Fayyad, Kevin Josey, Poonam Gandhi, Melanie Rua, Aayush Visaria, Benjamin Bates, Soko Setoguchi, Rachel C Nethery
IMPORTANCE: Despite biological plausibility, very few epidemiologic studies have investigated the risks of clinically significant bleeding events due to particulate air pollution. OBJECTIVE: To measure the independent and synergistic effects of PM2.5 exposure and anticoagulant use on serious bleeding events. DESIGN: Retrospective cohort study (2008-2016). SETTING: Nationwide Medicare population. PARTICIPANTS: A 50% random sample of Medicare Part D-eligible Fee-for-Service beneficiaries at high risk for cardiovascular and thromboembolic events...
March 7, 2024: Environmental Research
https://read.qxmd.com/read/38458580/atrial-thrombosis-prevalence-before-cardioversion-or-catheter-ablation-of-atrial-fibrillation-an-updated-systematic-review-and-meta-analysis-of-direct-oral-anticoagulants-versus-vitamin-k-antagonists
#18
JOURNAL ARTICLE
Federica Troisi, Pietro Guida, Nicola Vitulano, Federico Quadrini, Antonio Di Monaco, Giuseppe Patti, Massimo Grimaldi
Left atrial or left atrial appendage thrombosis (LAT) is contraindicated for cardiac ablation (CA) or cardioversion (CV) of atrial fibrillation (AF). This study was aimed to compare the frequency of LAT detected by transesophageal echocardiography (TEE) before CA or CV in patients with AF treated with direct oral anticoagulants (DOACs) or vitamin K antagonists (VKAs). We searched PubMed, Scopus, Web of Science, and Cochran Library databases from inception through July 13, 2023 to select studies reporting data on LAT identification before CA or CV using TEE in patients with AF treated with DOACs or VKAs...
March 7, 2024: American Journal of Cardiology
https://read.qxmd.com/read/38458228/pearls-and-pitfalls-in-the-measurement-of-direct-oral-anticoagulants
#19
JOURNAL ARTICLE
Giuseppe Lippi, Emmanuel J Favaloro
Due to their widespread use, testing for direct oral anticoagulants (DOACs) has become urgent in certain clinical situations. Screening based on widely available, rapid, and simple hemostasis assays such as prothrombin time, activated partial thromboplastin time, or even diluted Russel Viper venom time may provide sufficient evidence of "over-coagulation" and could be used "in small/peripheral/spoke laboratories" as an emergency strategy, but is not thought to be reliable for driving clinical decision making...
March 8, 2024: Seminars in Thrombosis and Hemostasis
https://read.qxmd.com/read/38443248/the-safety-and-efficacy-of-noacs-versus-lmwh-for-thromboprophylaxis-after-tha-or-tka-a-systemic-review-and-meta-analysis
#20
REVIEW
Kai Ding, Wei Yan, Yifan Zhang, Jiaxing Li, Congxin Li, Chunhui Liang
The differences in the safety and efficacy of anticoagulation between different types of new oral anticoagulants(NOACs) and low molecular weight heparin(LMWH) are still controversial. The main purposes of this study were to analyze safety and efficacy of NOACs versus LMWH for thromboprophylaxis, and perform subgroup analyses stratified by individual NOACs and different populations after total hip arthroplasty (THA) or total knee arthroplasty (TKA). Literature search was performed in PubMed, EMBASE, Cochrane Library, CNKI and Wanfang databases until June 31, 2022...
March 4, 2024: Asian Journal of Surgery
keyword
keyword
10533
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.